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Abstract
A mass spectrometry-based assay combining the specificity of selected reaction monitoring and
the protein ion activation capabilities of electron transfer dissociation was developed and
employed for the rapid identification of hemoglobin variants from whole blood without previous
proteolytic cleavage. The analysis was performed in a robust ion trap mass spectrometer
operating at nominal mass accuracy and resolution. Subtle differences in globin sequences,
resulting with mass shifts of about one Da, can be unambiguously identified. These results
suggest that mass spectrometry analysis of entire proteins using electron transfer dissociation
can be employed on clinical samples in a workflow compatible with diagnostic applications.
Key words: Electron transfer dissociation, Single reaction monitoring, Top-down mass
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Introduction
H emoglobin is the major protein of red blood cells. It is atetramer of approximately 64 kDa composed of two α
chains and two β (hemoglobin A, or HbA), δ (hemoglobin A2),
or γ (hemoglobin F) chains. It plays a major physiological role
in carrying oxygen from the lungs to all tissues and organs.
Inherited disorders of hemoglobin, also called hemoglobinop-
athies, are the most common monogenic disorders. It is indeed
estimated that 7 % of the world population are mutation
carriers. Hemoglobinopathies represent a major health burden
with approximately 300,000 children born affected annually [1,
2]. These autosomal recessive genetic diseases are divided into
two groups: first, thalassaemias, characterized by the reduction
of synthesis of one or more normal globin chains; second,
disorders related to the synthesis of a structurally abnormal
globin chain (hemoglobin variants). The most common
hemoglobin variant is hemoglobin S (HbS) that causes sickle
cell disease. Another common variant is hemoglobin C (HbC),
responsible for moderate to severe anemia and splenomegaly.
Biological diagnosis of hemoglobinopathies is a complex
stepwise procedure involving hematological tests for pheno-
type determination, liquid chromatography (LC) and electro-
phoretic methods for the identification and quantification of
normal and mutant hemoglobin, and molecular biology
techniques to characterize the underlying genetic defect [3].
This multistep process requires multiple analytical laboratory
equipments, is often associated with long turnaround times,
and must be performed in specialized laboratories by experi-
enced teams. We postulate that top-down mass spectrometry
(MS) with electron transfer dissociation (ETD) is a way to
simplify and to speed up this complex laboratory procedure.
Major improvements were recently brought to MS for protein
analysis. Selected reaction monitoring (SRM), an old tool in
the MS toolbox, was rediscovered for polypeptide quantifica-
tion [4]. With SRM, a particular polypeptide ion is first
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activated into several fragment ions through collision-induced
dissociation (CID). The consecutive selection of a particular
polypeptide precursor ion (precursor mass) giving rise to a
precise fragment ion (fragment mass) within one experiment,
referred to as a transition, confers a high specificity to these
assays. This methodology can be used for the characterization
of hemoglobin variants by mass spectrometry, based on the
identification of the polypeptide containing a specific mutation
[5]. Although this approach is widely used in research
laboratories, most protocols still lack the reproducibility and
robustness needed in clinical laboratories [6]. These limitations
are largely due to the need of enzymatic digestion prior to MS
analysis [7]. Nevertheless, advances in intact protein (top-
down) analysis by MS offer a way to circumvent the digestion
problem. High-resolution tandemmass spectrometry (MS/MS)
of the full-length protein has been previously employed for the
characterization of hemoglobin variants [8]. Such methods rely
on the accurate and high-resolution detection of multiply
charged fragment ions [9, 10]. In parallel, alternative methods
to CID were introduced for the analysis of whole proteins.
Electron capture dissociation (ECD) was developed in 1998 by
Zubarev and co-workers as complementary technique to CID
to dissociate peptides and proteins [11]. Due to the rich and
specific distribution of peptide backbone fragments obtained
with this technique, entire proteins could be sequenced,
including identification of post-translational modifications.
The more recently introduced ETD uses gas-phase radical
anions instead of electrons for the dissociation reaction [12].
Combined with high-resolution instrumentation, ETD was
used for the dissociation and structural analysis of proteins up
to 150 kDa [13]. While ECD is preferentially performed in a
high-end and expensive Fourier transform ion cyclotron
resonance mass spectrometers, ETD can be done in less
expensive and robust ion trap instruments. Such ion trapping
devices can be used with similar modes of operation to SRM,
termed SRM-like or pseudo-SRM, to identify and quantify
polypeptides over a wide dynamic range [14, 15]. Specific
polypeptide precursor ions are selected for activation in the same
manner as classical SRM, but the full fragment ion mass
spectrum is acquired. Extracted ion chromatograms specific to
compounds to be identified and quantified are then reconstructed
in silico, once the full dataset is acquired. ETD can be used as an
ion activation method in ion trap instruments and hyphenated
with this mode of data acquisition [16]. Here, we combined ETD
activation and pseudo-SRM techniques for the top-down
analysis of full-length proteins, hemoglobin A and hemoglobin
variants, from clinical samples. The assay was performed on
chromatographic timescale, using a fast ion trap instrument with
ETD capabilities and a moderate resolving power.
Methods
Whole blood samples were collected in standard EDTA
vacutainers at Geneva University Hospitals and stored at 4 °C
before processing. All patients gave informed consent. The
ethics committee of the Geneva University Hospitals approved
this protocol (CE 11-042). A clinical hemoglobin analyzer
(Variant II HPLC system with Dual Kit reagents; Bio-Rad,
Hercules, CA, USA) was used to perform blood analysis
allowing sample characterization in parallel to ETD-MS
experiments.
For sample preparation, 250 μL of EDTA blood was
centrifuged at 3500g for 10 min. Then plasma was removed.
Red blood cells were suspended in 750 μL of cold solution of
0.9 % NaCl and centrifuged at 700g for 10 min. The
supernatant was removed. This cleaning step was repeated
two more times. Then, red blood cells were lysed by the
addition of 1750 μL of cold deionized water and centrifuged at
12,000g for 10 min. At the end of this step, hemoglobin was in
solution (supernatant). For direct MS infusion experiments, the
sample was desalted with a C18 macro spin column (Harvard
Apparatus, Harvard, MA, USA). Briefly, hemoglobin was
bound to the spin column with 5 % acetonitrile and 0.1 %
formic acid. After washing with the same solution, hemoglobin
was eluted with 50 % acetonitrile and 0.1 % formic acid. After
evaporation in a vacuum centrifuge, hemoglobin was dissolved
in 5 % acetonitrile and 0.1 % formic acid.
Hemoglobin analysis was performed on an Amazon speed
ETD mass spectrometer (Bruker Daltonics, Billerica, MA,
USA). ETD parameters were optimized to improve globin
chains activation. Hemoglobin was directly infused in the mass
spectrometer at 1 pmol/μL. Different ETD parameters were
tested such as number of reagent anions, ion/ion reaction time,
as well as ETD lowmass cut-off. The best combination of ETD
parameters for hemoglobin were ion accumulation target of
200,000, 400,000 reagent anions (set as ETD ICC), ETD cut-
off of at 160m/z, and reaction time of 60 ms. Three specific
fragments ions for hemoglobin A α and β chain, hemoglobin S
β chain, and hemoglobin C β chain were selected to allow
generating a specific signal for each protein (Table 1).
Hemoglobin solutions were injected into a RSLC ultimate
3000 nanoflow ultra high pressure liquid chromatograph
(Dionex Thermo Scientific, San Jose, CA, USA) coupled with
an amaZon speed ETD ion trap mass spectrometer. The
separation was done using a C8 trap column (20 mm, 300 Å
particles, inner diameter 100 μm, from Dionex Thermo
Scientific) followed by a C8 analytical column (150 mm,
300 Å particles, inner diameter 100 μm, Dionex Thermo
Scientific) heated to 34 °C. The proteins were infused in the
mass spectrometer through a Captive Spray nanoelectrospray
ionization source (Bruker Daltonics). The gradient started with
95 % phase A (water and 0.1 % formic acid) and 5 % of phase
B (acetonitrile and 0.1 % of formic acid) and increased to 90 %
in 20 min, at a flow rate of 300 nL/min. A volume of 2 μL of
hemoglobin solution, at a concentration of 4 pmol/μL was
injected. ETD parameters were: ion count control (ICC ETD):
400,000, ion–ion interaction time: 60 ms and cut-off 160m/z).
A scan speed of 32.500 Da/s was used as scan mode, isolation
width of 4m/z and an average of 5 was applied. All experiments
were performed in triplicate.
Data were analyzed using Data Analysis software ver. 4.0
(Bruker Daltonics). For LC experiments, extracted ion
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chromatograms were reconstructed post-acquisition. For
High-resolution analysis deconvolution, performed on a
qTOF maXis mass spectrometer (Bruker Daltonics), the
MaxEntropy algorithm, embedded in the data analysis
software, was used.
Results and Discussion
A hemoglobin extract prepared from whole EDTA blood
was analyzed using an ion trap mass spectrometer with ETD
capabilities. Figure 1a presents a mass spectrum of hemo-
globin A, with fully dissociated α and β chains. To perform
the most efficient tandem mass spectrometry with ETD, the
selected precursor ions should be highly charged because the
rate-determining step of the ETD reaction is dependent on
the square of the charge of the precursor ion [17]. Also, the
m/z distance between adjacent ions should be as wide as
possible to allow isolation of one unique chain prior to the
dissociation reaction. According to these criteria, the 18
times charged α chain (841.3m/z) and 19 times charged β
chain (836.1m/z) were chosen for isolation and subsequent
ETD. The top-down ETD mass spectrum of the β chain is
shown in Figure 1b. With the typical peak width below
0.4 Da, doubly charged fragment ions are unambiguously
assigned and fragment ions of the N-terminus are detected
up to the position 23 for the wild-type β chain (Figure 1b).
Specific fragment ions for α chain, wild-type β chain and
mutated β chains of hemoglobin S and C were selected for
the next set of experiments (Table 1). In these hemoglobin
variants, glutamic acid at position 6 of the β globin chain is
replaced by either valine (hemoglobin S) or lysine (hemo-
globin C).
ETD-based pseudo-SRM assays were then developed for
wild type and mutated hemoglobin chains. For these
experiments, hemoglobin was injected into a reversed-phase
nanoscale LC column hyphenated to the ion trap mass
spectrometer. Three specific fragment ions for each globin
chain were used for these assays (Table 1). The absence or
presence of a specific fragment ion in the extracted
chromatogram unambiguously indicated the presence or
absence of a specific chain. An extracted ion chromatogram
from a red blood cell extract is shown in Figure 2a. The red
blood cells extract was prepared from a patient suffering
from sickle cell anemia. The chromatograms clearly show
the presence of fragment ions specific to the β chain of
hemoglobin S. This patient was transfused with healthy
blood before blood sampling and, consequently, hemoglobin
Table 1. m/z Ratio and Nature of the Transitions Used for the Pseudo-SRM Assays
Chain Precursor ion Fragment ions
α [M+18H]18+ 841.3 m/z c1þ6 600.3 m/z c
1þ
7
728.4 m/z c1þ8 829.5 m/z
Hemoglobin A β [M+19H]19+ 836.1 m/z c1þ6 694.4 m/z c
1þ
7
823.4 m/z c1þ8 951.5 m/z
Hemoglobin S β [M+19H]19+ 834.5 m/z c1þ6 664.4 m/z c
1þ
7
793.5 m/z c1þ8 921.5 m/z
Hemoglobin C β [M+19H]19+ 836.1 m/z c1þ6 693.4 m/z c
1þ
7
822.5 m/z c1þ8 950.6 m/z
Figure 1. Hemoglobin A extracted from whole blood analyzed in an ion trap mass spectrometer. (a) Mass spectrum of
hemoglobin A. The α chain is labeled in blue, the β chain in red. (b) ETD tandem mass spectrum of the β chain of hemoglobin A,
with sequence-specific fragment ions
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Figure 2. (a)Reversed-phase nanoHPLC chromatograms of pseudo-SRM ETD assays for hemoglobin α chain, hemoglobin A β chain
and hemoglobin S β chain. Blood was collected from a patient homozygous for hemoglobin S transfused with normal blood. The Blood
used for this experiment had 30% of normal hemoglobin (hemoglobin A) and 70% of mutated hemoglobin (hemoglobin S). In blue, the
extracted ion chromatogramof three transitions specific to theα globin chain (841.3m/z→600.3m/z; 728.4m/z; 829.5m/z, corresponding to
[M+18H]18+→c6
1+; c7
1+; c8
1+ ion). In red, the extracted ion chromatogramof three transitions specific to the hemoglobin A β chain (836.1
m/z→694.4m/z; 823.4m/z; 951.5m/z, corresponding to [M+19 H]19+→c6
1+; c7
1+; c8
1+ ion). In green, the extracted ion chromatogram
corresponding to three transitions specific to mutated hemoglobin S β chain (transition: 834.5m/z→664.4m/z; 793.5m/z; 921.5m/z,
corresponding to [M+19 H]19+→c6
1+; c7
1+; c8
1+ ion). (b) Reversed-phase nanoHPLC chromatograms for hemoglobin α chain,
hemoglobin A β chain, and hemoglobin C β chain. Blood was collected from a patient homozygous for hemoglobin C. In blue, the
extracted ion chromatogram of three transitions specific to the hemoglobin α chain (841.3m/z→600.3m/z; 728.4m/z; 829.5m/z,
corresponding to [M+18 H]18+→c6
1+; c7
1+; c8
1+ ion). In red, the extracted ion chromatogram of three transitions specific to the
hemoglobin A β chain (transition: 836.1m/z→694.4m/z; 823.4m/z; 951.5m/z, corresponding to [M+19 H]19+→c6
1+; c7
1+; c8
1+ ion). In
orange, the extracted ion chromatogram of three transitions specific to hemoglobin C β chain (836.1m/z→693.4m/z; 822.5m/z; 950.6m/z,
corresponding to [M+19 H]19+→c6
1+; c7
1+; c8
1+ ion). The small trace in the hemoglobin A β chain corresponds to the second isotopic
peak of hemoglobin C fragments. (c) Reversed-phase nanoHPLC chromatograms for hemoglobin α chain, hemoglobin A β chain and
hemoglobin C β chain. Red-blood cell extracts fromHbA andHbCpatients weremixed to simulate a HbC heterozygote. Both chains are
now detected with similar ion abundance. The transitions are the same as in (b)
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A was detected in addition to hemoglobin S. Blood analysis
using a clinical hemoglobin analyzer (Variant II HPLC
system, Bio-Rad) indicated that hemoglobin S and hemo-
globin A concentrations were 70 % and 30 %, respectively.
As shown in Figure 2a, this mutated/wild-type β chain ratio
was well preserved in chromatograms from the pseudo-SRM
assay. The same protocol was then applied on a blood
sample from a patient homozygous for hemoglobin C. This
single point mutation yields a mass shift of only 1 Da,
instead of 30 Da for the hemoglobin S mutation. This very
small mass shift prevents discrimination between hemoglo-
bin A and hemoglobin C β chains on the mass spectrum,
Figure 3. Hemoglobin A and C, extracted from whole blood and analyzed with a high resolution mass spectrometer (qTOF
maXis, Bruker Daltonics, Bremen, Germany). (a) Mass spectra of the two hemoglobins with a zoom in the isotopic distribution
of hemoglobin β chain at 20+ and 19+ charge states. Upper mass spectrum: hemoglobin A, with the β chain highlighted in light
blue. Lower mass spectra: hemoglobin C, with the β chain highlighted in green. The calculated monoisotopic mass (MH+) of
HbA β chain is 15858.26 Da, and of HbC β chain is 15857.31 Da. (b) Deconvoluted mass spectra of β chains from the spectra
above. The upper spectrum corresponds to the β chain of hemoglobin A, the lower spectrum to the β chain of hemoglobin C.
Although high resolution permits the separation of individual isotopes, hemoglobin A and C cannot be distinguished. The
observed distortion in the isotopic pattern of the β chain after deconvolution is not explained by the authors.
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even with high resolution mass spectrometers (Figure 3).
Activation and detection of protein fragment ions was
necessary to distinguish the two variants. Accordingly, the
pseudo-SRM ETD-MS assay accurately detected the pres-
ence of hemoglobin C in patient’s blood (Figure 2b). A
chromatographic peak corresponding to three specific
transitions of hemoglobin C β chain was indeed clearly
visible on the chromatogram (Figure 2b). Because the
second isotopic peak of the selected fragments for hemo-
globin C β chain overlaps with the fragment ions of non-
mutated β chain, a weak specific signal was also detected in
the extracted chromatogram corresponding to the β chain of
HbA. However, this analytical interference had no impact on
the detection of the HbC variant. To demonstrate this, a red
blood cell extract from a control patient (HbA) was mixed
with a red blood cell extract from a patient homozygote for
HbC, simulating a patient heterozygote for HbC. As shown
in Figure 2c, HbA and HbC were clearly detected. The
isotopic interference corresponding to HbA β chain repre-
sented only a small fraction of the ion abundance of HbC β
chain (Figure 2b) in the HbC heterozygote patient. The ion
abundances are similar for HbA β chain and HbC β chain for
this HbC heterozygote scenario.
It is also important to mention that the full tandem mass
spectrum is acquired during the pseudo-SRM ETD MS
analysis. Thus, specific fragment ions from other sequences
and/or hemoglobin mixtures can always be tested post-
acquisition to confirm or invalidate the presence of other
hemoglobin variants. However, it should be specified that,
despite the high specificity of the MS analyzer, the exact
identification of some variants can be hampered because
different mutations producing different amino acid changes
but yielding identical or very similar mass shifts may occur
at the same position in a globin chain. For example,
hemoglobin Machida, a very rare variant identified in one
Japanese family and characterized by the replacement of
glutamic acid at position 6 of the β globin chain by a
glutamine, yields a mass shift of 0.98. Hemoglobin Machida
therefore cannot be distinguished from hemoglobin C (mass
shift of 0.95) using the pseudo-SRM ETD MS method with
an ion trap. This limitation of MS approaches will have to be
considered in future developments for potential clinical use
with instruments operating at nominal mass accuracy.
However, similar problems are encountered with any
screening technique currently used for hemoglobin disorders
diagnosis, such ion-exchange chromatography or capillary
electrophoresis. Taking in consideration the ethnic origin of
the patient and confirmation by molecular biology is the way
to address such ambiguous cases.
Finally, the limit of detection of the pseudo-SRM
ETD-MS assay was also assessed. Blood from a healthy
patient was mixed with blood from a patient homozy-
gous for hemoglobin S in various ratios and analyzed
using the same protocol. Results showed that concen-
trations as low as 4 % of HbS were easily detected
(Figure 4).
Conclusions
Our data show that intact proteins can be specifically analyzed
in an ion trap mass spectrometer by pseudo-SRM-ETD. The
use of a fast and simple sample preparation protocol combined
with a robust, fast, and easy to operate ion trap mass
spectrometer allows relatively short turn-around-times (less
than 3 hours from blood to results) and makes this methodol-
ogy potentially suitable for application in clinical laboratories.
The power of presented MS-based assay is the possibility to
screen for multiple mutations on several polypeptide chains in a
single experiment, suggesting that it has the potential for
significantly improving diagnostic procedures for hemoglobin
variants. Experiments are currently in progress on a cohort of
patients with various hemoglobin variants to expand the range
of detected mutations. Developments could also be made to
allow quantification of normal hemoglobin (A, A2, F) and
hemoglobin variants in the same assay.
Figure 4. Reversed-phase nano HPLC chromatograms for
hemoglobin β chains. In blue, the extracted ion chromatogram of
three transitions specific to hemoglobin A β chain (836.1m/z→
694.4m/z; 823.4m/z; 951.5m/z, corresponding to [M+19 H]
19+→c6
1+; c7
1+; c8
1+ ion). In pink, the extracted ion
chromatogram corresponding to three transitions specific
to mutated hemoglobin S β chain (transition: 834.5m/z→
664.4m/z; 793.5m/z; 921.5m/z, corresponding to [M+19 H]
19+→c6
1+; c7
1+; c8
1+ ion). (a) Hemoglobin purified from
whole blood of a healthy patient was used. As expected, no
signal for hemoglobin S β chain could be detected. (b) Whole
blood of a healthy patient spiked hemoglobin S to obtain a
concentration of 4% hemoglobin S in 96% hemoglobin A. The
signal for hemoglobin S β chain is clearly visible. The same data
processing was applied to both samples
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